Glaukos Corporation

Glaukos Corporation

GKOS · New York Stock Exchange

Glaukos Corporation (GKOS) is a Medical devices company in the Healthcare sector, listed on New York Stock Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Glaukos Corporation in 2026. The next earnings report is expected on November 4, 2026.

Earnings calendar

Next earnings date

04 Nov 2026

In 75 days

EPS estimate

-0.13

Revenue estimate

156.0M

Past earnings

29 Jul 2026
EPS actual
-0.14 (+33.5%)
estimate -0.21
Revenue actual
185.6M (+23.0%)
estimate 150.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
29 Apr 2026
EPS actual
-0.18 (+35.9%)
estimate -0.28
Revenue actual
150.6M (+9.9%)
estimate 137.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
17 Feb 2026
EPS actual
-0.28 (-43.1%)
estimate -0.20
Revenue actual
143.1M (+4.9%)
estimate 136.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Glaukos Corporation beat consensus estimates in its latest earnings report, with EPS of negative $0.14 versus an estimate of negative $0.2105 and revenue of $185.61 million, 23.0% above expectations. Both EPS and revenue were also ahead of expectations in the previous report.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Sector
Healthcare
Industry
Medical devices
Country
United States
Exchange
New York Stock Exchange
CEO
Thomas William Burns
Employees
995
IPO date
25 Jun 2015
ISIN
US3773221029
Website
glaukos.com

Frequently asked questions

When does Glaukos Corporation (GKOS) next report earnings?

Glaukos Corporation (GKOS) is scheduled to report earnings on November 4, 2026.

What was Glaukos Corporation's most recent earnings date?

Glaukos Corporation (GKOS) last reported earnings on July 29, 2026.

Where is Glaukos Corporation stock listed?

Glaukos Corporation (GKOS) is listed on New York Stock Exchange.